Animals and plants express endogenous peptide antibiotics called defensins. Defensins show broad-spectrum antimicrobial activity, even against bacteria that have resistance to conventional antibiotics, which has made them viable candidates for new antibiotics.
Introduction
potency in the presence of complex fluids such as plasma, serum, saliva, and sputum [5, 8, 9] . In addition, high concentrations of human defensins reduce the viability of human cells [10] [11] [12] . Human α-defensins have also been reported to be associated with acute respiratory distress syndrome and pulmonary fibrosis [12] [13] [14] [15] . Furthermore, human defensins, especially α-defensins, induce the synthesis of inflammatory cytokines in endothelial and epithelial cells [11, 16] , which may result in an inexpedient inflammatory response, particularly during an infection. Although the toxicology and pharmacokinetics of human defensins have not been clarified, these characteristics of human defensins could be disadvantageous for their clinical application as antimicrobial agents.
Recently, defensin-like peptides have also been found in many kinds of organisms, such as plants, insects [17] , and fungi [18] . Plectasin is the first defensin-like peptide to be isolated from a fungus, the saprophytic ascomycete reported by Mygind and colleagues [19] . Recombinant plectasin is especially active against Streptococcus pneumoniae, including strains resistant to conventional antibiotics. Plectasin also cured mice of experimental peritonitis and pneumonia caused by S. pneumoniae as efficaciously as vancomycin and penicillin [19] . These findings showed that plectasin has properties that make it an attractive candidate for development into a human therapeutic agent. However, no report is available on the cytotoxicity of this peptide for human cells, and the induction of inflammatory cytokines by plectasin in human lung epithelial cells has not been studied. Furthermore, no report is available on the bioactivity of synthetic (as opposed to recombinant) plectasin.
To confirm whether plectasin is clinically valuable as an antibiotic, we evaluated the effects of synthetic plectasin on human lung cells, including cytotoxicity and induction of inflammatory cytokines, in addition to measuring its MIC against bacteria.
Materials and Methods
Reagents. Synthetic plectasin and human neutrophil peptide (HNP)-1, one of the human defensins, were purchased from Peptide Institute, Inc. (Osaka, Japan). Plectasin and HNP-1 were dissolved in saline yielding stock solutions and subsequently diluted to appropriate concentrations in broth for antimicrobial assays or in medium for cytokine assays.
Antimicrobial assay. The following bacteria were tested: penicillin-susceptible Enzyme-linked immunosorbent assay (ELISA). For the analysis of IL-8 production,
A549 cells grown to subconfluence (5.0 × 10 5 /dish) in 60-mm dishes were incubated for 24 h with culture medium alone (control) or 1.0 -50 μg/ml of plectasin or HNP-1.
Cell free supernatants were recovered by centrifugation and stored at −80°C until they were assayed. IL-8 levels were measured using a Quantikine human CXCL8/IL-8
ELISA kit according to the supplier's instructions (R&D Systems Inc., Minneapolis, MN, USA).
Statistical analysis.
Results were analyzed by Student's t test for comparison between two groups and by non parametric equivalents of analysis of variance (ANOVA) for multiple comparison. Significance was assumed at p < 0.05.
Results

MIC determination
To confirm that synthesized plectasin has an inhibitory effect against several species of Gram-positive bacteria [19] , an antimicrobial assay was performed first. As shown in Table 1 , growth of S. pneumoniae was markedly inhibited, suggesting that synthesized plectasin is a biologically active agent. Gram-negative bacteria, including H. influenzae and P. aeruginosa, were considerably more resistant to plectasin. The fungi C. glabrata and C. neoformans were resistant to plectasin (data not shown). Figure 1 shows that plectasin had the same MIC in the absence or presence of 3 -10% human serum. The
MICs against PSSP and PRSP were 2 μg/ml and 0.25 μg/ml, respectively.
Cytotoxicity of plectasin on human bronchial epithelial cells
Cell viabilities of A549 cells, NHBE, and NHLF were not affected by plectasin, as shown in Fig. 2 . In contrast, 10 μg/ml HNP-1 induced cell proliferation of A549 by 7.9% and NHBE by 13.6%, and 5 μg/ml HNP-1 induced cell proliferation of NHLF by 9.3%. Importantly, 50 μg/ml HNP-1 significantly reduced the viability of A549 by 54.3%, NHBE by 71.6%, and NHLF by 37.6% compared with control.
Effect of plectasin on IL-8 mRNA expression and protein production
mRNA expression of IL-8 in A549 cells was not elicited by plectasin (Fig. 3A) . In contrast to plectasin, IL-8 mRNA expression in A549 cells treated with HNP-1 significantly increased in a dose-dependent manner (Fig. 3A) . Plectasin did not affect IL-8 protein secretion from A549 cells compared with medium alone (Fig. 3B ).
However, IL-8 protein secretion in A549 cells treated with HNP-1 significantly increased in a dose-dependent manner (Fig. 3B ).
Discussion
The major findings of the present study are that synthesized plectasin has antimicrobial activities against Gram-positive bacteria, especially S. pneumoniae, including strains resistant to conventional antibiotics and without cytotoxic effects on human A549 cells, NHBE, or NHLF. In addition, this agent did not induce IL-8 in A549
cells. These effects are apparently different from human defensins and the results indicate that plectasin offers promise as a new antibiotic against Gram-positive bacteria without side effects for systemic use.
First, we examined the antibacterial activity of purchased synthetic plectasin and observed almost the same activity, especially for S. pneumoniae, as reported by Mygind et al [19] . This shows that plectasin can be synthesized, and fully processed active plectasin can be effectively produced at high yields. Human defensin molecules are strongly cationic and act by binding to cellular membranes and directly perturbing membrane function [21] . A number of studies have demonstrated the ability of salts, in the form of NaCl, to inhibit the activity of defensin to various extents [22, 23] . In addition, human defensin requires low ionic strength and is deactivated by human serum components [5, 9] . We ascertained that HNP-1 did not show antibacterial activity against S. pneumoniae, S. aureus, or P. aeruginos in MH II broth, which contained beef extract, acid hydrolysate of casein, starch, 20 -25 mg/l calcium, and 10 -12.5 mg/l magnesium, at indicated pH 7.3 ± 0.1. [24] . As in traditional reports, MIC measurements of HNP-1 and other human defensins are required to be tested by radial diffusion assay [25] or colony count assay [26] . Meanwhile, we showed that plectasin was bactericidal in MH II broth by the procedure of CLSI [20] . This suggests that plectasin is stable against negatively-charged proteins and cations. In addition, we measured the MIC of plectasin against S. pneumoniae with human serum. Regardless of the presence of human serum, the results showed the same MICs against the same strains, which showed that the bactericidal activity of plectasin was not deactivated by human serum. These findings suggest that plectasin has advantages for systemic use, because it is considered stable under physiological conditions. In addition, the MIC and minimum bactericidal concentration of plectasin were almost the same. This property suggests that plectasin has altered the bacterial growth, an irreversible process leading to death within seconds to minutes of exposure [19] . Although the mechanism by which plectasin kills or inactivates bacteria is not fully understood, it is not a cationic protein and may act against bacteria by means different than those of other defensins. In this context, plectasin did not have antimicrobial activity against fungi and Gram-negative bacteria, including P. aeruginosa and H. influenzae, which are leading causes of lung infections. Thus, plectasin has a very narrow spectrum which is different from human defensins. Further studies are needed to clarify the exact mechanisms.
Second, we demonstrated that cell viabilities of A549 cells, NHBE, and NHFL were not affected by plectasin, which indicates that it has no clinically significant cytotoxicity against human bronchial and lung cells. In contrast, HNP-1 at more than 50 μg/ml significantly induced cell lysis [10] [11] [12] 16] . We have previously reported that 24 h treatment with >20 μg/ml of HNP-1 and >50 μg/ml of human β defensin-2 was cytotoxic to NHBE [11] , and 24 h treatment with >50 μg/ml of HNP-1 was cytotoxic to NHLF [12] . Though Mygind and colleagues have reported that plectasin was neither cytotoxic for murine fibroblasts or human epidermal keratinocytes, nor hemolytic for human erythrocytes [19] , this is the first study to examine the cytotoxicity of plectasin to human lung cells. We also demonstrated that plectasin did not induce cell proliferation while HNP-1 induces lung epithelial cell proliferation [27] . Our results indicate that plectasin could be used safely for humans, even if high doses might be necessary against gram-positive bacteria, which are more resistant to plectasin than S.
pneumoniae.
Finally, plectasin did not induce mRNA expression and protein production of IL-8 in A549 cells, whereas HNP-1 induces inflammatory cytokines from lung epithelial cells [11, 16] . IL-8 is one of the potent chemokines that are important in airway neutrophilic inflammation. IL-8 is produced by alveolar macrophages as well as by a number of non-inflammatory cells [28] . Increased levels of IL-8 in airway lining fluids have been reported in several airway inflammatory diseases, in which they were decreased by successful therapy [29, 30] . We and others have reported that HNP-1 induces the production of IL-8 from airway epithelial cells [11, 16] . We also have reported that α-defensin levels in bronchoalveolar lavage fluid (BALF) in patients with diffuse panbronchiolitis were highly elevated compared with healthy subjects and correlated with IL-8 levels in BALF [31] . These results suggest that IL-8 synthesis in airway Gene expression of IL-8 in A549 cells stimulated with medium alone (control) or 1 - 8  2  1  3 -2 -------13  -4  4 2 -------3  11  ------2 7 1 1 --11  -------8 3  ---10  --1 1 1 2 2 3 ----9 -----1 1 2 1 2 9 -10
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